Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways

Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma

(2018) Sophie Poty et al.   CLINICAL CANCER RESEARCH

Diversification of IgG effector functions

(2017) Stylianos Bournazos et al.   INTERNATIONAL IMMUNOLOGY

Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with 89Zr-5B1

(2017) Jacob L. Houghton et al.   MOLECULAR PHARMACEUTICS

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry

(2016) Jacob L. Houghton et al.   MOLECULAR CANCER THERAPEUTICS

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Obinutuzumab in hematologic malignancies: Lessons learned to date

(2015) Tim Illidge et al.   CANCER TREATMENT REVIEWS

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis

(2015) Yong-xi Song et al.   DISEASE MARKERS

Dinutuximab: First Global Approval

(2015) Sohita Dhillon   DRUGS

A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors

(2015) Daniela Kao et al.   Cell Reports

Clinically feasible approaches to potentiating cancer cell-based immunotherapies

(2015) VI Seledtsov et al.   Human Vaccines & Immunotherapeutics

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

(2015) D. J. DiLillo et al.   Cancer Immunology Research

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

(2015) Gregory T. Wurz et al.   Therapeutic Advances in Medical Oncology

Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions

(2014) L. Baudino et al.   JOURNAL OF IMMUNOLOGY

Type I and type II Fc receptors regulate innate and adaptive immunity

(2014) Andrew Pincetic et al.   NATURE IMMUNOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

(2013) Mahiuddin Ahmed et al.   FEBS LETTERS

Expression of carbohydrate-antigen sialyl-Lewis a on colon cancer cells promotes xenograft growth and angiogenesis in nude mice

(2013) Laura Terraneo et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycans as cancer biomarkers

(2011) Barbara Adamczyk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

(2011) R. Sawada et al.   CLINICAL CANCER RESEARCH

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Fc RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

(2010) F. Nimmerjahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS